More: Advances in Restless Legs Syndrome

Maximizing Outcomes in Patients With Restless Legs Syndrome: Focus on Relevance of the Disorder, Biological Basis, Diagnosis, and Management CME/CE

Author Information and Disclosures

Release Date: June 26, 2008; Valid for credit through June 26, 2009

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.5 nursing contact hours (0.5 contact hours are in the area of pharmacology)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

If you have not already done so, Medscape encourages you to take a self-assessment survey on Restless Legs Syndrome prior to engaging in this activity. Based on your answers to the survey, specific activities on RLS will be recommended for you and you will receive CME credit.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Boehringer
Learning Objectives
Upon completion of this activity, participants will be able to:
  1. Identify the essential criteria that are used to diagnose RLS
  2. Distinguish primary RLS from secondary RLS and identify potential etiologies of each
  3. Recognize the significant impact that symptoms of RLS may have on a patient's quality of life
  4. Evaluate treatment strategies for patients with differing levels of disease severity
Authors and Disclosures

Richard P. Allen, PhD
Disclosure: Richard P. Allen, PhD, has disclosed that he served as a consultant for GlaxoSmithKline, Boehringer Ingelheim, UCB, Xenoport, Sepracor, Novatis, Orion Pharma, Respironics, IM Systems, Pfizer, and Jazz. Dr. Allen has also disclosed that he received grant/research support from the National Institutes of Health and served on the speaker's bureau for GlaxoSmithKline and Boehringer Ingelheim. Dr. Allen also disclosed that his wife owns shares in and is president of IM Systems. Dr. Allen has served as an executive board member of the International Restless Legs Syndrome Study Group and the World Association of Sleep Medicine, and he was on the medical advisory board for the Restless Leg Syndrome Foundation.


Carol Peckham
Disclosure: Carol Peckham has disclosed no relevant financial relationships.


Stephanie Kushner
Disclosure: Stephanie Kushner is a member of the professional editorial group at Medscape and has reported no financial relationships relevant to the development of CME activities.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 1.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.